Investors might want to bet on Lyell Immunopharma (LYEL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

BofA lowered the firm’s price target on Lyell Immunopharma (LYEL) to 60c from $1 and keeps an Underperform rating on the shares. The firm said on Friday that Lyell provided a business update ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lyell Immunopharma (LYEL – Research Report) and Gilead Sciences (GILD – Research Report).